TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Stock Up 3.7 %

TLSI stock opened at $5.29 on Thursday. The firm has a market cap of $161.31 million, a PE ratio of -2.12 and a beta of 0.48. The business has a 50 day moving average of $5.31 and a 200-day moving average of $4.71. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42.

Analysts Set New Price Targets

Several brokerages have weighed in on TLSI. Roth Mkm reissued a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Lake Street Capital assumed coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $11.56.

Insider Transactions at TriSalus Life Sciences

In related news, CEO Mary T. Szela acquired 4,826 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the acquisition, the chief executive officer now owns 429,503 shares in the company, valued at approximately $2,327,906.26. This represents a 1.14 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, insider Sean Murphy acquired 15,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was bought at an average price of $5.31 per share, for a total transaction of $79,650.00. Following the acquisition, the insider now owns 182,732 shares of the company’s stock, valued at approximately $970,306.92. This trade represents a 8.94 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 54,856 shares of company stock worth $294,608. Company insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.